HC Wainwright Raises Earnings Estimates for Cabaletta Bio

Key Points

• HC Wainwright raised Cabaletta Bio’s Q3 2026 EPS estimate to a loss of $0.31 per share from $0.36, while projecting a $1.35 full-year 2026 loss and a return to positive EPS of $0.89 in 2030.
• Cabaletta Bio reported a quarterly loss of $0.34 per share, beating analysts’ consensus estimate of a $0.37 loss by $0.03.
• Analyst sentiment remains mixed: the stock has a “Moderate Buy” consensus rating and $15.33 average price target, although Wells Fargo recently cut its target to $3.00. Shares opened at $2.89 and remain well below their 12-month high of $4.23.

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - HC Wainwright upped their Q3 2026 earnings per share estimates for shares of Cabaletta Bio in a research note issued to investors on Friday, August 14th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.31) per share for the quarter, up from their prior estimate of ($0.36). The consensus estimate for Cabaletta Bio's current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Cabaletta Bio's Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.35) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.33) EPS, FY2027 earnings at ($1.29) EPS, FY2028 earnings at ($0.74) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at $0.89 EPS.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Cabaletta Bio in a research note on Friday, July 17th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Cabaletta Bio in a report on Wednesday, June 3rd. Wall Street Zen lowered shares of Cabaletta Bio from a "hold" rating to a "sell" rating in a research report on Saturday, June 13th. Wells Fargo & Company cut their target price on shares of Cabaletta Bio from $4.00 to $3.00 and set an "equal weight" rating for the company in a research note on Friday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price target on shares of Cabaletta Bio in a research report on Monday, May 4th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Cabaletta Bio presently has an average rating of "Moderate Buy" and an average price target of $15.33.

Cabaletta Bio Price Performance

Cabaletta Bio stock opened at $2.89 on Tuesday. The stock has a market capitalization of $471.23 million, a PE ratio of -1.84 and a beta of 3.30. The business has a 50 day simple moving average of $2.88 and a 200-day simple moving average of $3.06. Cabaletta Bio has a 12 month low of $1.40 and a 12 month high of $4.23.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.03.

Institutional Trading of Cabaletta Bio

Large investors have recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in Cabaletta Bio in the 2nd quarter valued at $34,000. Kestra Advisory Services LLC purchased a new position in Cabaletta Bio in the 1st quarter valued at $32,000. SummitTX Capital L.P. acquired a new stake in Cabaletta Bio during the 1st quarter worth $34,000. China Universal Asset Management Co. Ltd. acquired a new stake in Cabaletta Bio during the 4th quarter worth $34,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Cabaletta Bio during the fourth quarter worth $38,000.

Trending Headlines about Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Cabaletta Bio’s third and fourth quarters of 2026 to approximately $(0.31) from $(0.36), and increased its full-year 2026 loss estimate to $(1.35) from $(1.51). The firm also reduced projected losses for 2027 and 2028, including raising FY2027 EPS to $(1.29) from $(1.48) and FY2028 EPS to $(0.74) from $(1.41). These revisions suggest improving expectations for the company’s cost structure or cash runway.
• Neutral Sentiment: Despite the upgrades, HC Wainwright still expects Cabaletta Bio to remain unprofitable through 2029, with a forecasted return to positive EPS of $0.89 in 2030. The current-year consensus remains a loss of approximately $(1.34) per share, highlighting the stock’s dependence on clinical and commercial progress rather than near-term earnings.
• Negative Sentiment: HC Wainwright lowered its FY2029 EPS forecast to $(0.68) from $(0.64) and its FY2030 forecast to $0.89 from $1.11. These cuts temper the benefit of the earlier-year estimate increases and imply a slower long-term earnings trajectory.
• Negative Sentiment: Wells Fargo cut its Cabaletta Bio price target to $3.00. With the shares recently near $2.89, the revised target indicates limited near-term upside and may weigh on investor sentiment. Wells Fargo Cuts Cabaletta Bio Price Target

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source